NCT04920448

N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE

TOLERANCE STUDY OF N-ACETYLCYSTEINE FOR THROMBOLYSIS IN THE ACUTE PHASE OF ISCHEMIC STROKE / ETUDE DE TOLERANCE DE LA N-ACETYLCYSTEINE POUR LA THROMBOLYSE A LA PHASE AIGUË DE L'INFARCTUS CEREBRAL

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University Hospital, Caen · Academic / Other
• Sex: All
• Age: 18 Years – 86 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to assess the safety of N-Acetylcysteine as a thrombolytic agent in acute ischemic stroke, especially regarding the risk of hemorrhagic transformation.

Detailed description

Preclinical studies demonstrated that N-Acetylcysteine (NAC) is able to break von Willebrand Factor (VWF) multimers by bisulfide bond reduction. Since thrombi in stroke patients are rich in VWF, NAC could be used as a thrombolytic agent during the acute phase. This study aims at assessing the safety of NAC in combination with alteplase (rt-PA) at the acute phase of ischemic stroke.

Conditions

• Stroke, Ischemic

Interventions

Type	Name	Description
DRUG	N-Acetyl cysteine	Administered as specified in the treatment arm

Timeline

• Start date: 2021-06-16
• Primary completion: 2023-04-25
• Completion: 2024-04-25
• First posted: 2021-06-09
• Last updated: 2025-07-25

Locations

1 site across 1 country: France